Section 4 of 6
Clinical evidence
267 evidence topics · 52 sources
Study summaries
STOP-HAE
Objective
Registry brief summary
Primary and secondary objectives
Location and study date
Trial initiation, planned sites, and topline timing
Sites and countries reported at EAACI 2026
UK research ethics committee opinion
| Field | Reported value |
|---|---|
| REC reference | “25/NE/0161” |
| Date of REC opinion | “16 Oct 2025” |
| REC opinion | “Further Information Favourable Opinion” |
Topline data timing at the Q3 2026 update
Study design
Registry design details
| Field | Reported value |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Model description | “Randomized, double-blind, placebo-controlled study” |
| Masking | “Quadruple” |
| Masking description | “Double blinded” |
Washout, screening, and randomization
Post-dose visits and study duration
Participant timeline on the trial website
Transition to the long-term extension
Regulatory input on the phase 3 design
Eligibility criteria
Registry key inclusion criteria
Registry washout periods for long-term prophylaxis
EU record: laboratory criteria for the HAE diagnosis
EU record: suitability for on-demand treatment alone
EU record: renal function, ACE inhibitors, estrogens, and prior RNA therapy
Trial website criteria: prophylaxis discontinuation, medical history, and eDiary
Treatment
Registry interventions
| Intervention | Reported description |
|---|---|
| ADX-324 | “siRNA duplex oligonucleotide” |
| Placebo | “saline” |
Randomized treatment groups and injection volumes
| Treatment group | Reported value |
|---|---|
| Onvuzosiran every 6 months | “ADX-324 300 mg Q6M (1.5ml)” |
| Onvuzosiran every 3 months | “ADX-324 240 mg Q3M (1.2ml)” |
| Placebo, larger volume | “Placebo (1.5 ml) n=15” |
| Placebo, smaller volume | “Placebo (1.2 ml) n=15” |
Dose selection relative to the phase 2a doses
Pharmacodynamic target for the 300 mg dose
Number of active doses during the controlled period
On-demand treatment and home nursing visits
Study outcomes
Rationale for using monthly HAE attack rate as the primary endpoint
Exclusion of attacks before Day 22
Attack recording by daily eDiary
Guideline treatment goal: absence of attacks
“We recommend that the goals of treatment are to achieve total control of the disease and to normalize patients' lives.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Complete control of their disease, for HAE patients, translates to no longer having attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These treatments significantly reduce attack rates, and many patients achieve complete response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2a relationship between prekallikrein suppression and attacks
Secondary endpoints: registry definitions
Exploratory endpoint instruments
Validation of outcomes instruments: AECT scoring and cut-off
Validation of outcomes instruments: AECT development
“A 4-item AECT with recall periods of 4 weeks and 3 months was developed based on 106 potential items tested in 97 patients with mast cell mediator-induced (n = 49) or bradykinin-mediated recurrent AE (n = 48).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Its validity and reliability need to be determined in future independent studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Validation of outcomes instruments: AE-QoL minimal clinically important difference
Validation of outcomes instruments: AE-QoL content validation and psychometric evaluation
Validation of outcomes instruments: AE-QoL content validation in adults and adolescents
Validation of outcomes instruments: AE-QoL psychometric validation
Statistical analysis description
Number of participants (Planned and analyzed)
Registry planned enrollment
Planned participants per treatment group
| Treatment group | Planned participants |
|---|---|
| “ADX-324 300 mg Q6M (1.5ml)” | “n=30” |
| “ADX-324 240 mg Q3M (1.2ml)” | “n=30” |
| Placebo | “Placebo (1.2 ml) n=15 or (1.5 ml) n=15” |
Participants analyzed
No evidence found.
Description of analysis sets
Primary comparison and superiority criterion
Analysis populations
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
No results are available. The trial began in August 2025, enrollment is ongoing, and the estimated primary completion date is November 2027, with topline data expected by the end of 2027. Planned enrollment is approximately 90 participants: 30 per onvuzosiran group and 30 receiving placebo, divided into two injection volumes of 15 participants each. This sample size limits the precision of safety estimates and of any subgroup analysis. The primary endpoint compares only the 300 mg every-6-months group with placebo; the 240 mg every-3-months comparison is a secondary endpoint. The controlled period lasts 25 weeks, so participants in the every-6-months group receive one active dose and the controlled data do not cover a second 6-month dosing interval. Attacks before Day 22 are excluded from the primary analysis, so the primary endpoint does not describe protection during the first 3 weeks after the first dose. The comparator is placebo, so the trial does not provide a direct comparison with an approved long-term prophylactic agent. Eligibility is limited to adults with type I or type II HAE who have at least 1 investigator-confirmed attack in the first 4 weeks of screening or at least 2 in 8 weeks, who complete washout of long-term prophylaxis, and who are judged able to use on-demand treatment alone; HAE with normal C1 inhibitor, clinically significant renal or hepatic disease, and prior RNA- or DNA-based HAE therapy are excluded. The doses were selected from pharmacodynamic data in healthy volunteers and from the attack-free intervals of 3 participants with HAE whose phase 2a doses were lower or less frequent than the phase 3 regimens. The design is described only in the registry record, ethics summaries, and sponsor documents; no peer-reviewed protocol publication was identified.
ADX-324-101
Objective
Part A and Part B: objectives in the quarterly report
Part B: secondary objective and exploratory efficacy endpoints
Location and study date
Registry site, dates, and status
| Field | Reported value |
|---|---|
| Location | “Adelaide, South Australia, Australia, 5000 CMAX Clinical Research” |
| Study start | “Study Start (Actual) 2022-12-14” |
| Primary completion | “Primary Completion (Estimated) 2027-12-31” |
| Study completion | “Study Completion (Estimated) 2027-12-31” |
| Status | “Active, not recruiting” |
Part A: country at first dosing
Part A interim analysis: follow-up at the time of analysis
Part A and Part B: data cutoff of the workshop abstract
Part A and Part B: data dates of the AAAAI poster figures
Part B: safety and efficacy data cutoffs in the prospectus
Part B: data cutoff of the November 2026 presentation
Study design
Registry design: two parts
Part A: randomization ratio and sentinel dosing
Part A: cohorts as described in the prospectus
Part A and Part B: cohorts as described in the workshop abstract
“A Phase 1, healthy volunteer placebo-controlled single dose escalation study of ADX-324 in 6 cohorts (0.4 mg/kg to 6 mg/kg) and 1 cohort administered 2 doses of 140 mg ADX-324 or placebo 3 months apart, and an open-label Phase 2a study in HAE patients with ADX-324 administered SC every 6 months was conducted” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“in a phase 2a, dose range finding study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Part A and Part B: cohorts as described in the EAACI abstract
Part A interim: planned dose escalation and planned HAE study
Part B: continued dosing after the objectives were assessed
Eligibility criteria
Part A: inclusion criteria for healthy volunteers
Part A: selected exclusion criteria for healthy volunteers
Part B: inclusion criteria for participants with HAE
Part B: selected exclusion criteria for participants with HAE
Treatment
Registry interventions
| Intervention | Description |
|---|---|
| ADX-324 | “siRNA duplex oligonucleotide” |
| Placebo | “saline” |
Part A: weight-based cohorts in the pharmacokinetic figure
| Cohort | Dose as printed |
|---|---|
| Phase 1 cohort 1 | “Phase 1 Cohort 1 (0.4 mg/mkg)” |
| Phase 1 cohort 2 | “Phase 1 Cohort 2 (1.0 mg/mkg)” |
| Phase 1 cohort 3 | “Phase 1 Cohort 3 (2.0 mg/mkg)” |
| Phase 1 cohort 4 | “Phase 1 Cohort 4 (4.0 mg/mkg)” |
| Phase 1 cohort 5 | “Phase 1 Cohort 5 (6.0 mg/mkg)” |
| Phase 2 cohort 1 | “Phase 2 Cohort 1 (2.0 mg/mkg)” |
Part A: repeat-dose cohort
Part B: doses and dosing interval
Part B: doses as stated in the workshop abstract
“Three HAE patients have been dosed with ADX-324 at 2 mg/kg (n = 1, approximately 125 mg) and 245 mg (n = 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“one HAE patient was dosed at 122 mg and two patients were dosed at 245 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Part B: doses as stated in the EAACI poster
Study outcomes
Rationale for using adverse event incidence as the primary endpoint
Registry primary outcome measures
Registry secondary outcome measures: prekallikrein and kallikrein
Part B: prekallikrein-kallikrein reduction as a predictor of attacks
Part B: suppression threshold proposed for an attack-free state
Same target: prekallikrein concentration and attack rate with donidalorsen
“These reductions in HAE attack rates were associated with corresponding reductions in mean plasma prekallikrein trough concentrations of 73% in the donidalorsen Q4W group and 47% in the donidalorsen Q8W group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reductions in predicted prekallikrein concentrations were correlated with reductions in predicted HAE attack rates” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Registry planned enrollment
Part A: participants in the AAAAI poster
Part A and Part B: participants in the February 2026 release
Part A: participants by total dose group in the pharmacodynamic figure
| Total dose group | Group as printed |
|---|---|
| Placebo | “ph1, 0 mg (n=11)” |
| Above 0 to 100 mg | “ph1, >0-100 mg (n=13)” |
| Above 100 to 200 mg | “ph1, >100-200 mg (n=8)” |
| Above 200 to 250 mg | “ph1, >200-250 mg (n=6)” |
| Above 250 to 300 mg | “ph1, >250-300 mg (n=3)” |
| Above 300 to 350 mg | “ph1, >300-350 mg (n=4)” |
| Above 350 mg | “ph1, >350 mg (n=4)” |
| 300 mg plus or minus 25 mg | “ADX-324 300 mg +/- 25 mg (n=5)” |
Part B: participants enrolled
Description of analysis sets
Part A: summary statistic for prekallikrein-kallikrein reduction
Part B: longest follow-up in the AAAAI abstract
Part B: attack-free interval measured from approximate full inhibition
Results
Participant disposition
Registry recruitment status and results posting
Part A: completion and withdrawals
Part B: participants followed and one withdrawal
Part A and Part B: discontinuations due to adverse events
Baseline characteristics
No evidence found.
Efficacy results
Part A interim: prekallikrein nadir by weight-based dose
Part A: dose dependence of prekallikrein-kallikrein reduction
Part A: 6 mg/kg cohort, reduction at nadir and at 6 months
Part A: 300 mg plus or minus 25 mg, reduction at nadir and at Day 169 in the prospectus
Part A: 6 mg/kg cohort in the November 2026 presentation
Part A: 300 mg figures as attributed in the November 2026 presentation
Part A: 300 mg plus or minus 25 mg in the AAAAI poster
Part A: 300 mg dose in the February 2026 release
Part A: 300 mg plus or minus 25 mg in the workshop abstract
Part B: prekallikrein-kallikrein reduction compared with healthy volunteers at similar doses
Part B: attack-free period after the first dose, August 2026 cutoff
Part B: attack-free period after the first dose, November 2026 cutoff
Part B: attacks in relation to prekallikrein-kallikrein reduction
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Part A interim: severity and most frequent adverse event
Part A: most common adverse events and laboratory changes
Part A: serious adverse events by dose in the November 2026 presentation
Part B: safety through the August 2026 cutoff
Part A and Part B: serious adverse events and repeat dosing in the AAAAI poster
Part A and Part B: serious adverse events in the EAACI poster
Part A and Part B: tolerability in the February 2026 release
Part A and Part B: tolerability in the congress abstracts
Study limitations
Summary
Part A enrolled healthy volunteers aged 18 to 55 years with a body mass index of 18 to 30 kg/m2, so its pharmacodynamic and safety findings come from a population without HAE. Its dose groups were small: the AAAAI poster lists 3 to 13 participants per total dose group, 5 participants in the 300 mg plus or minus 25 mg group, and the prospectus reports the 6 mg/kg results for 4 participants, 3 of whom were below LLOQ at nadir.
Part B was open-label and uncontrolled and enrolled 3 participants, one of whom withdrew for administrative reasons. Its doses (122.5 mg or 245 mg every 6 months) differ from the phase 3 regimens of 300 mg every 6 months and 240 mg every 3 months. All phase 2a dosing was every 6 months, and the November 2026 presentation describes the 3-month attack-free result as an “Observed 100% Q3M attack-free rate in Phase 2a after the first dose”.
No baseline characteristics, baseline attack rates, on-treatment attack rates, or quality-of-life results were identified. Efficacy is reported as attack-free intervals of individual participants and as an association between attacks and the degree of prekallikrein-kallikrein reduction, and the prospectus figure marks the approximate time of full inhibition (about Day 22) and the point 3 months after the first dose. The proposed threshold differs between documents: “> 70%” in the workshop abstract and “>80%” in the prospectus and other sponsor documents.
The results are available only in congress abstracts, posters, press releases, a corporate presentation, and SEC filings. No peer-reviewed full article was identified, the registry record shows “No Results Posted”, and primary completion is estimated for 2027-12-31. The documents use data cutoffs from December 2024 to November 2026.
The documents report different numbers for Part A: 43 participants (32 onvuzosiran, 11 placebo) in 5 cohorts in the February 2026 release; 49 participants (38 onvuzosiran, 11 placebo) in the posters and the prospectus; and 5, 6, or 7 cohorts in different documents. The prospectus attributes the 94% nadir and 84% six-month reductions to the 6 mg/kg cohort, while the November 2026 presentation attributes them to 6 mg/kg on one page and to 300 mg plus or minus 25 mg on another. The first Part B dose is written as 122 mg, 122.5 mg, or approximately 125 mg.
Safety reporting gives one frequency, 28.9%, attached to headache and injection-site reaction in Part A, and no counts for creatine phosphokinase changes or liver enzyme increases. Serious adverse events are described variously as absent, absent when treatment-related, or absent when drug-related. No immunogenicity data and no electrocardiogram results were identified, although electrocardiogram change is a registry primary outcome.
Interim and early-phase results: sponsor statement
ADX-324-302
Objective
Registry brief summary
Location and study date
UK research ethics committee opinion
| Field | Reported value |
|---|---|
| REC reference | “26/SC/0102” |
| Date of REC opinion | “12 May 2026” |
| REC opinion | “Further Information Favourable Opinion” |
Study design
Registry design details
| Field | Reported value |
|---|---|
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Double” |
Treatment duration and maintenance of the core-study blind
Sponsor description of the extension
Attack recording during the extension
Eligibility criteria
Registry inclusion and exclusion criteria
Eligibility assessment at the end of the core study
Treatment
Regimens by core-study assignment
Registry interventions
| Intervention | Reported description |
|---|---|
| ADX-324 Dose Level 1 | “siRNA duplex oligonucleotide” |
| ADX-324 Dose Level 2 | “siRNA duplex oligonucleotide” |
Study drug cost to participants
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Secondary endpoint: registry definition
Statistical analysis description
Number of participants (Planned and analyzed)
Registry planned enrollment
Participants analyzed
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
No results are available. The extension began in April 2026 and has an estimated primary completion date of June 2030. Allocation is non-randomized and every participant receives onvuzosiran, so the extension has no concurrent control group for safety or attack-rate comparisons. The core-study assignment remains masked through alternating onvuzosiran and placebo injections in the every-6-months group; the extension itself is not blinded to active treatment. Enrollment is limited to participants who completed STOP-HAE, and participants with a negative reaction to study drug in STOP-HAE are excluded, so the extension population may under-represent participants who did not tolerate or did not continue onvuzosiran. The primary endpoint is the incidence and severity of treatment-emergent adverse events through Month 36, and the monthly attack rate is a secondary endpoint. Planned enrollment is approximately 90 participants, which limits the detection of uncommon adverse events. No statistical analysis plan or analysis population definitions have been published.
OASIS-HAE
Objective
Prophylaxis objective
Location and study date
Registered study locations and countries
| Field | Reported value |
|---|---|
| Country | “Belgium” |
| Country | “Bulgaria” |
| Country | “Canada” |
| Country | “Denmark” |
| Country | “France” |
| Country | “Germany” |
| Country | “Israel” |
| Country | “Italy” |
| Country | “Netherlands” |
| Country | “Poland” |
| Country | “Spain” |
| Country | “Turkey (Türkiye)” |
| Country | “United Kingdom” |
| Country | “United States” |
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using HAE attack rate per four weeks as the primary endpoint
Primary clinical endpoint: attack rate over the 24-week treatment period
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
| Population | Participants |
|---|---|
| Planned total | “84” |
Actual treated populations
| Population | Participants |
|---|---|
| Donidalorsen every four weeks | “45”View highlighted excerpt for this quote |
| Donidalorsen every eight weeks | “23”View highlighted excerpt for this quote |
| Placebo | “22”View highlighted excerpt for this quote |
Description of analysis sets
Results
Participant disposition
Treatment exposure
| Population | Participants |
|---|---|
| Treated | “90”View highlighted excerpt for this quote |
Baseline characteristics
Efficacy results
Mean attack rate per four weeks: weeks 1–25 in the publication
| Treatment | Attack rate |
|---|---|
| Donidalorsen every four weeks | “0.44”View highlighted excerpt for this quote |
| Donidalorsen every eight weeks | “1.02”View highlighted excerpt for this quote |
| Placebo | “2.26”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
AE-QoL improvement relative to placebo at week 25: every-four-week regimen
AE-QoL total score: clinically meaningful improvement at week 24
“A greater proportion of the donidalorsen Q4W group achieved clinically meaningful improvement in AE‐QoL total score (≥ 6 points) vs. the placebo group (88.1% vs. 45.0%; odds ratio [OR], 12.2; 95% confidence interval [CI], 2.8 to 54.3; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most Q8W patients (71.4%) also achieved the MCID, but while numerically larger, the difference between the donidalorsen Q8W and placebo groups was not statistically significant (OR, 3.5; 95% CI, 0.8 to 14.3; p = 0.087).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AE-QoL domain scores from baseline to week 24
“Patients reported decreases (improvements) in mean functioning domain scores from 45.2 at baseline to 8.0 at week 24 in the donidalorsen Q4W group and 51.2 to 18.2 in the donidalorsen Q8W group, compared with a decrease from 46.6 to 33.3 in the placebo group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean fears/shame domain scores improved from 53.2 to 22.3, 54.8 to 27.1, and 57.0 to 51.6 in the donidalorsen Q4W, donidalorsen Q8W, and placebo groups, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the nutrition domain, patients reported improvements in means from 32.7 to 11.0 (Q4W), 36.9 to 17.6 (Q8W), and 36.4 to 28.5 (placebo).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No significant differences in the change in the fatigue/mood domain were observed between the donidalorsen and placebo groups, but scores improved from 41.9 to 28.5 (Q4W), 39.5 to 31.4 (Q8W), and 34.1 to 30.3 (placebo).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Angioedema Control Test: change from baseline and disease control at week 24
“Least‐squares mean (LSM) changes from baseline to week 24 in AECT total score were statistically significantly larger in both the Q4W (7.2 points; 95% CI, 5.9 to 8.4) and Q8W donidalorsen (5.2 points; 95% CI, 3.4 to 7.0) groups than in the placebo group (1.2 points; 95% CI, −0.7 to 3.0; Q4W vs. placebo p < 0.001; Q8W vs. placebo p = 0.003).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As reported previously, at week 24, 91% of patients in the donidalorsen Q4W group reported well‐controlled disease vs. 41% of patients in the placebo group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“a significantly greater proportion of patients in the donidalorsen Q8W group (74%) reported well‐controlled disease at week 24 compared with the placebo group (OR vs. placebo, 4.1; 95% CI, 1.2 to 14.4; p = 0.028).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“51% and 48% of patients in the donidalorsen Q4W and Q8W groups, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“reported complete disease control (AECT = 16; Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient Global Impression of Severity at week 24
“82% of donidalorsen Q4W patients reporting improvement, that is, less severe disease at week 24 compared with baseline” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the 44% reporting improvements in disease severity in the placebo group (OR, 6.2; 95% CI, 1.4 to 28.2; p = 0.018; Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Work productivity and activity impairment at week 24
“Mean presenteeism, the percent loss of productivity while at work/school, improved from 25.6% at baseline to 4.0% at week 24 in the donidalorsen Q4W group compared with a decrease from 30.7% to 19.8% in the placebo group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall work/school impairment decreased from 28.4% to 4.7% in the donidalorsen Q4W group vs. 35.2% to 22.7% in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients reported improvements in the overall activity impairment domain from 35.4% to 10.5% in the donidalorsen Q4W group vs. 34.7% to 21.2% in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Numerical improvements from baseline to week 24 were observed in all WPAI domains in the donidalorsen Q8W group, but these changes did not reach significance vs. placebo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Study limitations
Summary
The trial treated 90 participants: 45 received donidalorsen every 4 weeks, 23 received donidalorsen every 8 weeks, and 22 received placebo. The randomized comparison does not describe outcomes beyond Week 25. The full analysis set comprised “all randomized patients who received at least 1 dose of Study Drug”, and attack counts were analyzed with a “Poisson regression model and Pearson chi-square scaling of standard errors”. The placebo group of 22 participants and the every-8-week group of 23 participants limit precision for between-group estimates and for uncommon adverse events; injection-site reactions occurred in 11 of 45 participants (24%) receiving every-4-week dosing. Donidalorsen was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, baseline attack rates, observation periods, and attack-rate definitions (attacks per 4 weeks in this trial) can affect the reported rates.
OASISplus
Objective
Open-label extension cohort objective
“The majority of patients enrolled in OASIS-HAE (83/90, 92.2%) rolled over into the open-label extension (OLE) cohort of the ongoing OASISplus study (NCT05392114), which is designed to evaluate the long-term safety and efficacy of donidalorsen treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort objective
“The Switch cohort of the OASISplus study (NCT05392114) evaluated the long‐term safety and efficacy of donidalorsen in patients who switched from a long‐term prophylactic treatment (LTP) to donidalorsen with 1‐year outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Registered study dates and enrollment status
| Field | Reported value |
|---|---|
| Study start | “2022-07-13” |
| Primary completion, estimated | “2026-12” |
| Study completion, estimated | “2027-03” |
| Recruitment status | “Active, not recruiting” |
Data cutoff for the year 1 analyses
“This prespecified analysis of the ongoing OASISplus study reports results for patients who completed the OLE through Week 52 (including 28 additional days of follow-up, defined as the on-treatment period) as of a January 27, 2025 data cut.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OASISplus is an ongoing, global, open‐label study designed to evaluate the long‐term safety and efficacy of donidalorsen 80 mg administered SC in patients with HAE‐C1INH‐Type1 and HAE‐C1INH‐Type2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“(data cutoff date: January 27, 2025)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Open-label, single-group design with two cohorts
“OASISplus is an ongoing multicenter, phase 3 study composed of 2 cohorts: a de novo cohort of patients who switched from prior LTPs to donidalorsen 80 mg Q4W (Switch cohort), and an OLE cohort of patients who rolled over from the OASIS-HAE study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Open-label extension cohort: rollover from OASIS-HAE
“Patients were eligible to enroll in the OLE if they successfully completed the OASIS-HAE study or if they had five or more attacks/month for two consecutive months after Week 4 of OASIS-HAE, in which case they could rollover early into the OLE and receive donidalorsen Q4W” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort: age and stable prior prophylaxis
“the Switch cohort included adults and adolescents aged ≥ 12 years on stable prophylactic doses of plasma‐derived or recombinant C1INH via SC or intravenous (IV) administration, lanadelumab, or berotralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort: exclusions for concomitant medicines and prior oligonucleotides
Treatment
Open-label extension cohort: assignment to every-4-week or every-8-week dosing
“Patients who received donidalorsen 80 mg or placebo Q4W in OASIS-HAE received donidalorsen 80 mg Q4W in OASISplus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who received donidalorsen 80 mg or placebo Q8W in OASIS-HAE received donidalorsen 80 mg Q8W in OASISplus, unless they were not attack-free during the last 8 weeks (Weeks 16–24) in OASIS-HAE, in which case they received donidalorsen Q4W in OASISplus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort: transition algorithm from prior prophylaxis
“patients were switched from their prior LTP administered during the baseline period to donidalorsen 80 mg administered SC Q4W with no washout period using a prespecified algorithm that was designed to minimize HAE attacks during the switching process” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who received prior lanadelumab received their last dose 14 ± 3 days prior to the first dose of donidalorsen on Day 1 of the study, and patients who received prior berotralstat or C1INH continued the treatment for 14 ± 3 days after Day 1 of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using treatment-emergent adverse event incidence as the primary endpoint
Primary endpoint: incidence and severity of treatment-emergent adverse events
Secondary endpoints: attack rate and angioedema quality of life
“Rates of HAE attacks were time-normalized per every 4-week period (28 days), also termed monthly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AE-QoL is a validated, 17-item, disease-specific, self-administered questionnaire with four domains calculated using a scale of 0 to 100, with lower scores indicating better QoL, and a minimal clinically important difference of ≥6 points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort: attack-rate baseline measured on prior prophylaxis
Exploratory endpoint: disease control on the Angioedema Control Test
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
| Population | Participants |
|---|---|
| Actual enrollment, both cohorts | “154” |
Open-label extension cohort
“The OLE cohort included 83 patients (Q4W, n=69 [83%]; Q8W, n=14 [17%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No formal sample size calculations were performed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The sample size for the OLE cohort was dictated by the number of patients enrolled in the OASIS-HAE study and their eligibility for the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort by prior prophylactic treatment
“A total of 65 patients were enrolled in the original cohort, and of these, 64 (98.5%) patients received at least one dose of donidalorsen (prior lanadelumab, n = 31; prior berotralstat, n = 11; prior C1INH, n = 22 [SC, n = 15; IV, n = 7])” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Switch cohort sample size was instead determined per clinical assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Open-label extension cohort: safety and full analysis sets
“results were summarized with descriptive statistics including observed mean, median, patient numbers, and percentages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All endpoints were analyzed using data from the safety and full analysis sets, both defined as all patients who received at least one dose of donidalorsen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort: descriptive analysis without a comparator group
“As OASISplus was an open‐label study in which all patients received donidalorsen, no comparator group and no formal sample size calculations were performed to address group differences.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The safety set was used for the primary outcome and all safety analyses. The efficacy endpoints were summarized using descriptive statistics in the full analysis set.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Open-label extension cohort: completion and discontinuation at year 1
“As of the data cutoff date (January 27, 2025), 75 patients (90%) completed Week 52 in the OLE study. Eight patients (10%) discontinued treatment early due to voluntary withdrawal (n = 4), AEs (n = 3), or pregnancy (n = 1; Supplemental Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“six patients changed from donidalorsen Q8W in OASIS-HAE to Q4W dosing in OASISplus, and 19 patients from the OASIS-HAE placebo group were assigned to receive donidalorsen Q4W” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort: completion and discontinuation at year 1
“54 (83.1%) patients completed 1 year of treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 11 (16.9%) patients discontinued donidalorsen treatment, including 8 (12.3%) patients who switched from lanadelumab and 3 (4.6%) patients who switched from SC or IV C1INH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients who received lanadelumab before switching to donidalorsen, the most common reason for treatment discontinuation was lack of efficacy (n = 4)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No patients who received prior berotralstat therapy discontinued treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Open-label extension cohort: demographics and baseline attack rate
| Characteristic, total (N=83) | Reported value |
|---|---|
| Age, years, mean (SD) | “37 (14)”View highlighted excerpt for this quote |
| Age 12 to 17 years, n (%) | “7 (8.4)”View highlighted excerpt for this quote |
| Female, n (%) | “45 (54.2)”View highlighted excerpt for this quote |
| White, n (%) | “76 (91.6)”View highlighted excerpt for this quote |
| Baseline HAE attack rate, mean (SD) | “3.4 (2.1)”View highlighted excerpt for this quote |
Switch cohort: demographics and baseline attack rate on prior prophylaxis
| Characteristic, total (N=64) | Reported value |
|---|---|
| Age, years, mean (SD) | “42 (15)”View highlighted excerpt for this quote |
| Age 12 to 17 years, n (%) | “4 (6.3)”View highlighted excerpt for this quote |
| Female, n (%) | “38 (59.4)”View highlighted excerpt for this quote |
| White, n (%) | “57 (89.1)”View highlighted excerpt for this quote |
| Baseline HAE attack rate, mean (SD) | “0.9 (1.3)”View highlighted excerpt for this quote |
Efficacy results
Open-label extension cohort: reduction in attack rate from OASIS-HAE baseline, weeks 0 to 52
“The mean reduction in HAE attack rate over the 52-week OLE was 94% (median, 98%) in the Q4W group (including patients who moved from Q8W dosing in OASIS-HAE to Q4W in the OLE) and 95% (median, 96%) in the donidalorsen Q8W group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This corresponded to a reduction in mean (SD) time-normalized monthly HAE attack rate from 3.5 (2.13) and 2.9 (2.06) at baseline to 0.3 (0.45) and 0.1 (0.10) over Weeks 0 to 52 in the Q4W and Q8W dosing groups, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension cohort: attack-free participants, weeks 4 to 52
Switch cohort: change in attack rate from baseline on prior prophylaxis, weeks 0 to 52
“Overall, HAE attack rates decreased by 67.6% from a mean (SD) of 0.85 (1.3) at baseline (on their prior HAE prophylactic therapy) to 0.28 (0.4) over the treatment period through 1 year (Weeks 0–52) of the study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who switched from lanadelumab experienced a 63.9% decrease, patients who switched from berotralstat experienced an 83.1% decrease, and patients who switched from C1INH experienced a 50.7% decrease in HAE attack rate from baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Open-label extension cohort: AE-QoL and disease control at week 52
“The mean (SD) reduction from baseline in AE-QoL total score at Week 52 was 27.8 (16.1) points overall, 28.1 (15.7) points in the Q4W group, and 26.7 (18.2) points in the Q8W group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“68 of 70 (97%) patients with an AECT evaluation at both OASIS-HAE baseline and OASISplus Week 52 reported well-controlled disease (AECT score ≥10)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort: AE-QoL, disease control, and treatment satisfaction at week 52
“AE‐QoL total score improved by a mean (SD) of 12.2 (17.6) points from baseline to Week 52 in the overall population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, after 52 weeks of treatment with donidalorsen, 90.4% of patients had well‐controlled disease (prior lanadelumab, n/N = 18/22 [81.8%]; prior berotralstat, n/N = 10/10 [100%]; prior C1INH, n/N = 19/20 [95.0%]; Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall mean (SD) global satisfaction domain score on the TSQM‐II improved from 75.7 (21.5) at baseline to 89.4 (15.3) at Week 52” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Open-label extension cohort: treatment-emergent adverse events at year 1
| Event, total (N=83) | Participants, n (%) |
|---|---|
| Any TEAE | “75 (90.4)”View highlighted excerpt for this quote |
| TEAE related to study drug | “22 (26.5)”View highlighted excerpt for this quote |
| TEAE leading to discontinuation | “3 (3.6)”View highlighted excerpt for this quote |
| Any serious TEAE | “7 (8.4)”View highlighted excerpt for this quote |
Open-label extension cohort: serious events, liver enzymes, and bleeding
“Seven (8%) patients, all of whom received donidalorsen Q4W, reported serious AEs; none were considered drug related.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One patient in the Q4W group died by suicide, considered unrelated to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the other had a 30-day persistence of alanine aminotransferase levels at >5 times the upper limit of normal (ULN) with normal blood bilirubin concentration that resolved after treatment discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no major bleeding events or treatment-related trends in activated partial thromboplastin time observed during the treatment period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension cohort: hypersensitivity reaction after year 1
“one patient experienced a serious type 1 hypersensitivity reaction characterized by rash, dyspnea, perioral swelling, and chest pain after receiving the 29th dose of donidalorsen Q4W (being on this regimen for approximately 2.5 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort: treatment-emergent adverse events at year 1
| Event, total (N=64) | Participants, n (%) |
|---|---|
| Any TEAE | “56 (87.5)”View highlighted excerpt for this quote |
| TEAE related to study drug | “24 (37.5)”View highlighted excerpt for this quote |
| TEAE leading to discontinuation | “1 (1.6)”View highlighted excerpt for this quote |
| Any serious TEAE | “1 (1.6)”View highlighted excerpt for this quote |
Switch cohort: most common treatment-related adverse events
“The most common treatment‐related AEs occurring in more than 5% of the overall population were injection‐site erythema (10.9%), injection‐site pruritus (10.9%), injection‐site pain (7.8%), and fatigue (7.8%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunogenicity in the open-label extension
Study limitations
Summary
OASISplus is an open-label study with no comparator group, and both cohort publications summarized outcomes with descriptive statistics and no formal sample size calculation.
The open-label extension cohort enrolled 83 of the 90 OASIS-HAE participants (69 receiving donidalorsen every 4 weeks and 14 every 8 weeks). Participants continued every-8-week dosing only if they had been attack-free during the last 8 weeks of OASIS-HAE, so the every-8-week group of 14 participants was selected for response. The 94% and 95% reductions are measured from the OASIS-HAE baseline, before any prophylaxis in that trial.
The Switch cohort dosed 64 participants who had been receiving lanadelumab (31), berotralstat (11), or C1 inhibitor (22). Its attack-rate baseline was the screening period on the prior prophylactic treatment (mean 0.85 attacks per month), so the 67.6% reduction is a within-participant comparison with continued prior prophylaxis, without randomization or blinding. Eleven participants (16.9%) discontinued during the first year, including 4 who had switched from lanadelumab and discontinued for lack of efficacy. The subgroups by prior therapy contain 11 to 31 participants, which limits precision for comparisons between them.
In both cohorts, 89.1% to 91.6% of participants were White. The registry lists an actual enrollment of 154 participants across the study, and the two cohort publications report 83 and 65 participants enrolled. The year 1 publications report data through January 27, 2025, and the registry lists treatment for up to 157 weeks, with primary completion estimated for December 2026.
HELP
Objective
Location and study date
Study design
Eligibility criteria
Treatment
Subcutaneous lanadelumab regimens; placebo comparator
| Regimen | Dose and interval |
|---|---|
| Lower-dose monthly | “150 mg q4wks” |
| Higher-dose monthly | “300 mg q4wks” |
| Every two weeks | “300 mg q2wks” |
Study outcomes
Rationale for using monthly HAE attack rate as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Primary analysis population and model
Results
Participant disposition
Study completion
| Disposition | Participants, n (%) |
|---|---|
| Completed | “113 (90.4%)”View highlighted excerpt for this quote |
Baseline characteristics
Age at baseline
| Characteristic | Reported value |
|---|---|
| Mean age, years | “40.7”View highlighted excerpt for this quote |
Efficacy results
Mean monthly attack rate over 26 weeks
| Treatment | Attacks per month |
|---|---|
| Lanadelumab 150 mg every four weeks | “0.48”View highlighted excerpt for this quote |
| Lanadelumab 300 mg every four weeks | “0.53”View highlighted excerpt for this quote |
| Lanadelumab 300 mg every two weeks | “0.26”View highlighted excerpt for this quote |
| Placebo | “1.97”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary
The trial randomized 125 participants to three lanadelumab regimens (28, 29, and 27 participants) or placebo (41 participants), and 113 (90.4%) completed the study. The primary analysis used the “Intent-to-Treat” population and a “Poisson regression model”. Because three active regimens shared the randomization, each lanadelumab group contained 27 to 29 participants, which limits precision for comparisons between regimens and for uncommon adverse events; injection-site reactions were reported in 45% to 57% of lanadelumab groups and in 34% of the placebo group. The placebo-controlled period does not describe outcomes over longer treatment. Lanadelumab was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, run-in requirements, baseline attack rates, and observation periods can affect the reported attack rates.
VANGUARD
Objective
Prophylactic treatment objective
Location and study date
Number of trial centers
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using monthly HAE attack rate as the primary endpoint
Primary endpoint: six-month observation
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized and included populations
| Population | Participants |
|---|---|
| Randomized | “65”View highlighted excerpt for this quote |
| Garadacimab included | “39”View highlighted excerpt for this quote |
| Placebo included | “25”View highlighted excerpt for this quote |
Description of analysis sets
Safety population: minimum treatment exposure
Results
Participant disposition
Baseline characteristics
Baseline sex distribution
| Characteristic | Participants, n (%) |
|---|---|
| Female | “38 (59%)”View highlighted excerpt for this quote |
Efficacy results
Published monthly attack rates and relative treatment effect
| Outcome | Reported value |
|---|---|
| Garadacimab: mean monthly attack rate | “0·27”View highlighted excerpt for this quote |
| Placebo: mean monthly attack rate | “2·01”View highlighted excerpt for this quote |
| Difference in means, percent | “-87%”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
AE-QoL total score by attack-free status: post hoc analysis
“Patients ages ≥ 18 years completed the Angioedema Quality of Life (AE-QoL) questionnaire in both studies; scores were evaluated post hoc by attack-free status.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the pivotal phase III and phase III OLE studies, 62% and 60% of patients, respectively, were attack-free.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the pivotal phase III study, the mean AE-QoL total score improved with garadacimab, from 38.8 (day 1) to 6.6 (month 6) for attack-free patients (n = 19) and to 18.4 for patients with one or more attacks (n = 14) versus a change in mean AE-QoL total score from 43.7 to 40.5 with placebo (n = 20).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Study limitations
Summary
Of 65 randomized participants, 64 were included in the reported comparison (39 receiving garadacimab and 25 receiving placebo) after one participant was randomized in error. Allocation was 3:2 across 28 centers, and the placebo group of 25 participants limits precision for between-group estimates and for uncommon adverse events. Eligibility required “two or more acute HAE attacks”. The primary endpoint, the number of HAE attacks per month, does not describe outcomes over longer treatment. No health-related quality of life result for this trial was identified. Garadacimab was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, run-in requirements, baseline attack rates, and observation periods can affect the reported attack rates.
APeX-2
Objective
Location and study date
Study design
Eligibility criteria
Run-in attack requirement
Treatment
Berotralstat 110-mg and 150-mg regimens: route and administration
Study outcomes
Rationale for using monthly HAE attack rate as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized and treated populations
| Population | Participants |
|---|---|
| Randomized | “121”View highlighted excerpt for this quote |
| Berotralstat 110 mg treated | “41”View highlighted excerpt for this quote |
| Berotralstat 150 mg treated | “40”View highlighted excerpt for this quote |
| Placebo treated | “39”View highlighted excerpt for this quote |
Description of analysis sets
Results
Participant disposition
Treatment exposure
| Population | Participants |
|---|---|
| Received at least one dose | “120”View highlighted excerpt for this quote |
Baseline characteristics
Median baseline attack rate during the prospective run-in period
Efficacy results
Monthly attack rates during the 24-week comparison
| Treatment | Attacks per month |
|---|---|
| Berotralstat 110 mg | “1.65”View highlighted excerpt for this quote |
| Berotralstat 150 mg | “1.31”View highlighted excerpt for this quote |
| Placebo | “2.35”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
AE-QoL total score at week 24 in APeX-2
“In both APeX‐2 and APeX‐J, 43% of patients receiving berotralstat 150 mg achieved minimal clinically important difference (MCID) in Angioedema QoL (AE‐QoL) total score, compared with 17% in the placebo group at 6 months” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“least square mean difference [LSMD] of change from baseline: −4.9 in APeX‐2 [p = 0.188]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled APeX-2 and APeX-J post hoc analysis: AE-QoL at week 24
“We conducted a post hoc trial analysis to evaluate the impact of berotralstat on HRQoL versus placebo through 24 weeks, and the long‐term effects of treatment up to 96 weeks, using pooled APeX‐2 and APeX‐J patient data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 47 patients treated with berotralstat (40 from APeX‐2; 7 from APeX‐J) and 45 treated with placebo (39 from APeX‐2; 6 from APeX‐J) were included in the analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At Week 24, patients receiving berotralstat demonstrated significantly greater improvement versus placebo in AE‐QoL total (LSMD: −7.4; 95% CI: −14.3, −0.6; p < 0.05), functioning domain (LSMD: −10.9; 95% CI: −19.6, −2.3; p = 0.013), and fears/shame domain (LSMD: −8.7; 95% CI: −17.2, −0.2; p = 0.046) scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension: quality of life through 96 weeks
“Secondary endpoints included HAE attack rates and quality of life (QoL).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Clinically meaningful improvements in QoL were also observed, with the largest improvements in the functioning domain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Serious treatment-emergent adverse events considered drug related
Study limitations
Summary
The trial randomized 121 participants at 40 sites in 11 countries and treated 120: 41 received berotralstat 110 mg, 40 received berotralstat 150 mg, and 39 received placebo. Eligibility required “at least two investigator-confirmed attacks” during the run-in period, and the median baseline attack rate was 2.9 attacks per month. Efficacy was analyzed in the intent-to-treat population with a “negative binomial regression model”. The comparison does not describe outcomes over longer treatment, and groups of 39 to 41 participants limit precision for uncommon adverse events. No health-related quality of life result for this trial was identified. Berotralstat was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, baseline attack rates, and observation periods can affect the reported attack rates.
COMPACT
Objective
Location and study date
Trial locations and global end date
| Field | Reported value |
|---|---|
| Planned region | “Argentina” |
| Planned region | “Australia” |
| Planned region | “Canada” |
| Planned region | “European Union” |
| Planned region | “United States” |
| Global end of trial | “2015-10-12” |
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using HAE attack frequency as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
| Population | Participants |
|---|---|
| Whole trial | “100” |
Actual randomization
| Population | Participants |
|---|---|
| Randomized | “90”View highlighted excerpt for this quote |
Description of analysis sets
Results
Participant disposition
Study completion
| Disposition | Participants |
|---|---|
| Completed | “79”View highlighted excerpt for this quote |
Baseline characteristics
Baseline age
| Characteristic | Reported value |
|---|---|
| Median age, years (range) | “40 (12 to 72)” |
Efficacy results
Monthly attack-rate differences versus placebo
| Regimen | Mean difference, attacks per month |
|---|---|
| 40 IU/kg twice weekly | “-2.42”View highlighted excerpt for this quote |
| 60 IU/kg twice weekly | “-3.51”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
Post hoc HRQoL analysis: instruments and timing
“Post hoc analysis of data from the placebo-controlled, crossover phase III COMPACT study” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“HRQoL assessments at week 14 (last visit) included the European Quality of Life-5 Dimensions Questionnaire (EQ-5D-3L), the Hospital Anxiety and Depression Scale (HADS), the Work Productivity and Activity Impairment Questionnaire (WPAI), and the Treatment Satisfaction Questionnaire for Medication (TSQM).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HRQoL during subcutaneous C1-INH compared with placebo
“Compared with placebo (on-demand treatment alone), treatment with twice weekly C1-INH(SC) (both doses combined) was associated with better EQ-5D visual analog scale general health, less HADS anxiety, less WPAI presenteeism, work productivity loss, and activity impairment, and greater TSQM effectiveness and overall treatment satisfaction.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For each HRQoL measure, a greater proportion of patients had a clinically meaningful improvement during C1-INH(SC) treatment compared with placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Study limitations
Summary
The crossover trial randomized 90 participants against a planned enrollment of 100, and 79 participants completed it. Each participant received active treatment and placebo in sequence, and efficacy was evaluated “for the last 14 weeks of each treatment period” of the 32-week study, so period and carryover effects can influence the estimates. The efficacy results reported for this trial are mean differences from placebo in monthly attack rate (-2.42 attacks per month with 40 IU/kg and -3.51 with 60 IU/kg twice weekly), which are not directly comparable with absolute attack rates reported for parallel-group designs. No health-related quality of life result for this trial was identified. The trial enrolled participants aged 12 years or older, with a median age of 40 years (range, 12 to 72). Subcutaneous C1 inhibitor was compared with placebo only, so comparison with other prophylactic agents relies on cross-trial comparison.